PTP
EVFM

Platform Technology Partners’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Platform Technology Partners’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-867
Closed -$4K – 225
2022
Q1 		$4K Hold
867
– – ﹤0.01% 217
2021
Q4 		$5K Hold
867
– – ﹤0.01% 228
2021
Q3 		$10K Hold
867
– – ﹤0.01% 236
2021
Q2 		$15K Buy
+867
New +$16.4K 0.01% 260
2020
Q4 		$24K Buy
+667
New +$24.1K 0.01% 236

Other funds holding EVFM

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $486M AUM 50.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Platform Technology Partners's EVFM Position: Q2 2022 in Review

Platform Technology Partners sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 867 shares — an estimated $4K sold.

Platform Technology Partners first reported a position in EVFM in Q4 2020 and held it in 5 quarters. The position peaked at $24K in Q4 2020. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

  • Platform Technology Partners reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Platform Technology Partners sold 867 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $4K.
  • Platform Technology Partners first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Platform Technology Partners's Evofem Biosciences, Inc. Common Stock position peaked at $24K in Q4 2020.
  • 44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on Platform Technology Partners's 13F filing for Q2 2022, filed 4 Aug 2022.